2.67
2.91%
-0.08
アフターアワーズ:
2.69
0.02
+0.75%
前日終値:
$2.75
開ける:
$2.8
24時間の取引高:
11,279
Relative Volume:
0.30
時価総額:
$46.21M
収益:
$709.00K
当期純損益:
$-43.14M
株価収益率:
-0.26
EPS:
-10.27
ネットキャッシュフロー:
$-20.35M
1週間 パフォーマンス:
-4.64%
1か月 パフォーマンス:
-14.42%
6か月 パフォーマンス:
-5.32%
1年 パフォーマンス:
-33.08%
OncoCyte Corporation Stock (OCX) Company Profile
名前
OncoCyte Corporation
セクター
電話
510-775-0515
住所
1010 Atlantic Avenue, Suite 102, Alameda, CA
OCX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
OCX | 2.67 | 46.21M | 709.00K | -43.14M | -20.35M | -10.27 |
VRTX | 450.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 596.74 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 246.80 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 108.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
OncoCyte Corporation Stock (OCX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2022-05-24 | ダウングレード | Stephens | Overweight → Equal-Weight |
2022-03-14 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
2022-01-07 | 開始されました | Stephens | Overweight |
2022-01-06 | 再開されました | Piper Sandler | Overweight |
2021-03-17 | 再開されました | Needham | Buy |
2021-01-07 | アップグレード | The Benchmark Company | Speculative Buy → Buy |
2020-12-16 | アップグレード | Piper Sandler | Neutral → Overweight |
2020-11-30 | 開始されました | BTIG Research | Buy |
2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
2020-07-30 | 繰り返されました | The Benchmark Company | Speculative Buy |
2020-07-01 | ダウングレード | Piper Sandler | Overweight → Neutral |
2020-06-30 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
2020-06-02 | 開始されました | Needham | Buy |
2019-02-13 | 開始されました | Piper Jaffray | Overweight |
2019-01-29 | アップグレード | Janney | Neutral → Buy |
2018-12-19 | 再開されました | Lake Street | Buy |
すべてを表示
OncoCyte Corporation (OCX) 最新ニュース
Seasoned Financial executive joins Oncocyte as CFO - Reuters.com
PURA VIDA INVESTMENTS, LLC Expands Stake in OncoCyte Corp - GuruFocus.com
OncoCyte stock maintains Buy rating with Needham after GraftAssure RUO launch - Investing.com
OncoCyte Corporation (NASDAQ:OCX) Q3 2024 Earnings Call Transcript - Insider Monkey
OncoCyte: Q3 Earnings Snapshot - Darien Times
OncoCyte Corp (OCX) Q3 2024 Earnings Call Highlights: Progress i - GuruFocus.com
OncoCyte Corp (OCX) Q3 2024 Earnings Call Highlights: Progress in Transplant Testing and ... - Yahoo Finance
OncoCyte Corp Reports Q3 2024 Earnings and Strategic Updates - TipRanks
OncoCyte Corp (OCX) Q3 2024 Earnings: EPS of -$0.98 Misses Estimates, Revenue Falls Short at $115,000 - GuruFocus.com
Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025 - The Manila Times
Oncocyte Corporation (OCX) Quarterly 10-Q Report - Quartz
What to Expect from OncoCyte's Earnings - Benzinga
Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12 - ForexTV.com
OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com - MarketBeat
StockNews.com Initiates Coverage on OncoCyte (NASDAQ:OCX) - MarketBeat
Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles - The Manila Times
Oncocyte Corp expands equity incentive plan - Investing.com India
Oncocyte Corp expands equity incentive plan By Investing.com - Investing.com Australia
OncoCyte shares maintain Buy rating from Needham By Investing.com - Investing.com Nigeria
OncoCyte shares maintain Buy rating from Needham - Investing.com
OncoCyte Corp (OCX) Q2 2024 Earnings Call Highlights: Strategic Advances Amidst Financial Challenges - Yahoo Finance
Oncocyte reports breakthrough in breast cancer diagnostics - Investing.com
Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial - The Manila Times
Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial - StockTitan
Broadwood Partners L.P. buys Oncocyte shares for $3.88 million By Investing.com - Investing.com Australia
Oncocyte CFO acquires $99,999 worth of company shares By Investing.com - Investing.com South Africa
Oncocyte CFO acquires $99,999 worth of company shares - Investing.com
Broadwood Partners L.P. buys Oncocyte shares for $3.88 million - Investing.com
OncoCyte Secures Funding Through Private Share Sale - Yahoo Finance
OncoCyte Corporation announced that it expects to receive $10.203435 million in funding from Bio-Rad Laboratories, Inc. - Marketscreener.com
LENSAR reports inducement grants - Medical Buyer
Oncocyte Corporation enters into securities purchase agreement - Medical Buyer
Oncocyte Signs Leading Transplant Centers in US and Germany - The Manila Times
Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules - ForexTV.com
Sandfire Resources America Inc. Announces Incentive Plan Grants - The Manila Times
OncoCyte Corporation (OCX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):